This analysis was completed to evaluate the potential of the CPPs with tumor-targeting properties to provide a cytotoxic payload to HCC cells. We explored utilizing a CXCR4-focusing on peptide, T22, fused with cytotoxic peptide PE24, as a novel therapeutic strategy for CXCR4+ HCC cells. T22 was picked out since the https://https-1433119-com94937.blogsuperapp.com/31967213/the-definitive-guide-to-https-1433116-com